Designing an evidence-based Bayesian network for estimating the risk versus benefits of AstraZeneca COVID-19 vaccine
Helen J. Mayfield, View ORCID ProfileColleen L. Lau, View ORCID ProfileJane E. Sinclair, Samuel J. Brown, Andrew Baird, John Litt, Aapeli Vuorinen, Kirsty R. Short, Michael Waller, Kerrie Mengersen
doi: https://doi.org/10.1101/2021.10.28.21265588
Helen J. Mayfield
1School of Public Health, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia
Colleen L. Lau
1School of Public Health, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia
Jane E. Sinclair
2School of Chemistry and Molecular Biosciences, Faculty of Science, The University of Queensland, Brisbane, Queensland, Australia
Samuel J. Brown
2School of Chemistry and Molecular Biosciences, Faculty of Science, The University of Queensland, Brisbane, Queensland, Australia
Andrew Baird
3St Kilda Medical Group, St Kilda, Melbourne, Victoria, Australia
John Litt
4Discipline of General Practice, College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia
5Scientific Advisory Committee, Immunisation Coalition, Melbourne, Victoria, Australia
Aapeli Vuorinen
6Data Science Institute, Columbia University, New York, New York, U.S.A.
Kirsty R. Short
2School of Chemistry and Molecular Biosciences, Faculty of Science, The University of Queensland, Brisbane, Queensland, Australia
Michael Waller
1School of Public Health, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia
Kerrie Mengersen
7School of Mathematical Sciences, Faculty of Science, Queensland University of Technology, Brisbane, Queensland, Australia

Data Availability
All data produced in the present work are contained in the manuscript.
Posted October 29, 2021.
Designing an evidence-based Bayesian network for estimating the risk versus benefits of AstraZeneca COVID-19 vaccine
Helen J. Mayfield, Colleen L. Lau, Jane E. Sinclair, Samuel J. Brown, Andrew Baird, John Litt, Aapeli Vuorinen, Kirsty R. Short, Michael Waller, Kerrie Mengersen
medRxiv 2021.10.28.21265588; doi: https://doi.org/10.1101/2021.10.28.21265588
Designing an evidence-based Bayesian network for estimating the risk versus benefits of AstraZeneca COVID-19 vaccine
Helen J. Mayfield, Colleen L. Lau, Jane E. Sinclair, Samuel J. Brown, Andrew Baird, John Litt, Aapeli Vuorinen, Kirsty R. Short, Michael Waller, Kerrie Mengersen
medRxiv 2021.10.28.21265588; doi: https://doi.org/10.1101/2021.10.28.21265588
Subject Area
Subject Areas
- Addiction Medicine (240)
- Allergy and Immunology (521)
- Anesthesia (125)
- Cardiovascular Medicine (1419)
- Dermatology (158)
- Emergency Medicine (291)
- Epidemiology (10295)
- Gastroenterology (527)
- Genetic and Genomic Medicine (2629)
- Geriatric Medicine (254)
- Health Economics (497)
- Health Informatics (1733)
- Health Policy (789)
- Hematology (266)
- HIV/AIDS (565)
- Medical Education (273)
- Medical Ethics (83)
- Nephrology (289)
- Neurology (2461)
- Nursing (145)
- Nutrition (377)
- Oncology (1323)
- Ophthalmology (401)
- Orthopedics (146)
- Otolaryngology (237)
- Pain Medicine (168)
- Palliative Medicine (51)
- Pathology (343)
- Pediatrics (780)
- Primary Care Research (296)
- Public and Global Health (5007)
- Radiology and Imaging (893)
- Respiratory Medicine (681)
- Rheumatology (309)
- Sports Medicine (245)
- Surgery (298)
- Toxicology (45)
- Transplantation (140)
- Urology (108)